SineuGene Therapeutics' ALS drug Investigational New Drug application receives Chinese regulatory approval

South Rampart Pharma reports new study findings showing SRP-001 delivers central, non-toxic pain relief

NFL Biosciences and McLean Hospital collaborate to advance NFL-101 mechanism research

Neuraxpharm launches Neuraxpharm Australia

Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval

Mycovia Pharmaceuticals reports first participant enrolled in Phase 2 cryptococcal meningitis study

Estrella Immunopharma initiates second cohort in EB103 trial for advanced B-cell lymphomas

Dizal to present promising data in CLL, DLBCL and EGFR-Mutant NSCLC at ASCO 2025

Alar Pharmaceuticals reports first patient dosed in study of extended-release ketamine injection in treatment-resistant depression

EXACT Therapeutics secures UK patent for non-invasive brain drug delivery technology

Beijing Tide's AT2R antagonist TRD205 advances to Phase II trial in chronic post-surgical neuropathic pain

Belay Diagnostics partners with GenomOncology

Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment

Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda

Latigo Biotherapeutics' LTG-001 receives US FDA Fast Track designation